Dexamethasone nanomedicines for COVID-19

Twan Lammers; Alexandros Marios Sofias; Roy van der Meel; Raymond Schiffelers; Gert Storm; Frank Tacke; Steffen Koschmieder; Tim H Brümmendorf; Fabian Kiessling; Josbert M Metselaar

doi:10.1038/s41565-020-0752-z

Dexamethasone nanomedicines for COVID-19

Twan Lammers, Alexandros Marios Sofias, Roy van der Meel, Raymond Schiffelers, Gert Storm, Frank Tacke, Steffen Koschmieder, Tim H Brümmendorf, Fabian Kiessling, Josbert M Metselaar

Department of Hepatology and Gastroenterology, Charité University Medicine, Berlin, Germany.
Department of Medicine IV (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), RWTH Aachen University, Aachen, Germany.
Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

Original language	English
Pages (from-to)	622-624
Number of pages	3
Journal	Nature Nanotechnology
Volume	15
Issue number	8
DOIs	https://doi.org/10.1038/s41565-020-0752-z
Publication status	Published - Aug 2020

Keywords

Betacoronavirus/drug effects
COVID-19
Coronavirus Infections/drug therapy
Dexamethasone/therapeutic use
Humans
Nanomedicine
Pandemics
Pneumonia, Viral/drug therapy
SARS-CoV-2

Access to Document

10.1038/s41565-020-0752-z

s41565-020-0752-zFinal published version, 5.28 MBLicence: Taverne

Cite this

@article{1a431a6cb7b549818501073a9f4f0482,

title = "Dexamethasone nanomedicines for COVID-19",

abstract = "Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.",

keywords = "Betacoronavirus/drug effects, COVID-19, Coronavirus Infections/drug therapy, Dexamethasone/therapeutic use, Humans, Nanomedicine, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2",

author = "Twan Lammers and Sofias, {Alexandros Marios} and {van der Meel}, Roy and Raymond Schiffelers and Gert Storm and Frank Tacke and Steffen Koschmieder and Br{\"u}mmendorf, {Tim H} and Fabian Kiessling and Metselaar, {Josbert M}",

year = "2020",

month = aug,

doi = "10.1038/s41565-020-0752-z",

language = "English",

volume = "15",

pages = "622--624",

journal = "Nature Nanotechnology",

issn = "1748-3387",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Dexamethasone nanomedicines for COVID-19

AU - Lammers, Twan

AU - Sofias, Alexandros Marios

AU - van der Meel, Roy

AU - Schiffelers, Raymond

AU - Storm, Gert

AU - Tacke, Frank

AU - Koschmieder, Steffen

AU - Brümmendorf, Tim H

AU - Kiessling, Fabian

AU - Metselaar, Josbert M

PY - 2020/8

Y1 - 2020/8

N2 - Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

AB - Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

KW - Betacoronavirus/drug effects

KW - COVID-19

KW - Coronavirus Infections/drug therapy

KW - Dexamethasone/therapeutic use

KW - Humans

KW - Nanomedicine

KW - Pandemics

KW - Pneumonia, Viral/drug therapy

KW - SARS-CoV-2

U2 - 10.1038/s41565-020-0752-z

DO - 10.1038/s41565-020-0752-z

M3 - Article

C2 - 32747742

SN - 1748-3387

VL - 15

SP - 622

EP - 624

JO - Nature Nanotechnology

JF - Nature Nanotechnology

IS - 8

ER -

Dexamethasone nanomedicines for COVID-19

Abstract

Keywords

Access to Document

Fingerprint

Cite this